Canine Cancer Immunotherapy: New Treatments on the Horizon for 2026

Cancer is the leading cause of death in dogs over the age of ten. Approximately one in four dogs will develop cancer during their lifetime, and the treatment options — surgery, chemotherapy, and radiation — have remained largely unchanged for decades. In 2026, a wave of new immunotherapy research is poised to change that landscape, offering targeted treatments with fewer side effects and better outcomes.

The Morris Animal Foundation announced four new canine health studies funded for 2026, with cancer research taking center stage. Among the most promising is a project developing monoclonal antibody therapy specifically for mast cell tumors — the most common skin cancer in dogs.

What Is Immunotherapy?

Traditional chemotherapy works by killing rapidly dividing cells. This approach is broadly effective but causes significant collateral damage, destroying healthy cells alongside cancerous ones. The side effects — nausea, immune suppression, organ damage — are the same trade-offs human cancer patients face.

Immunotherapy takes a fundamentally different approach. Instead of directly attacking cancer cells, it trains or enhances the dog’s own immune system to recognize and destroy them. Because the immune system can distinguish between cancer cells and healthy tissue with far greater precision than chemotherapy drugs, immunotherapy promises more targeted treatment with fewer side effects.

Several types of immunotherapy are being developed for dogs, including monoclonal antibodies, cancer vaccines, checkpoint inhibitors, and engineered bacteria that deliver cancer-fighting proteins directly into tumor cells.

Mast Cell Tumor Breakthrough

Mast cell tumors (MCTs) account for up to 20% of all skin tumors in dogs. They range from low-grade growths that surgery alone can cure to aggressive high-grade tumors that metastasize and resist conventional treatment. Breeds with elevated risk include boxers, Boston terriers, golden retrievers, Labrador retrievers, and pugs.

Dr. Marietta M. Ravesloot-Chavez at the University of California, Davis, is leading a Morris Animal Foundation-funded study to develop a monoclonal antibody therapy targeting canine mast cell tumors. The approach targets KIT, a receptor protein found on the surface of mast cell tumor cells.

In human medicine, monoclonal antibodies have transformed cancer care — drugs like trastuzumab (Herceptin) for breast cancer and rituximab for lymphoma have saved millions of lives. This research aims to bring similar precision to veterinary oncology, creating antibodies that bind specifically to KIT on cancer cells while leaving healthy cells unharmed.

Current treatment for advanced mast cell tumors typically involves the tyrosine kinase inhibitors toceranib (Palladia) or masitinib, which also target KIT but through a different mechanism and with broader side effects. A monoclonal antibody approach could provide a more precise alternative with potentially fewer adverse effects.

Engineered Bacteria as Cancer Fighters

Another frontier in canine cancer immunotherapy involves engineering bacteria that can enter cancer cells and deliver cancer-fighting proteins from within. This approach, also funded by Morris Animal Foundation for 2026, treats bacterial organisms as miniature drug delivery vehicles that home in on the oxygen-depleted environments found inside solid tumors.

Early research has shown that certain bacterial strains naturally accumulate in tumors. By engineering these bacteria to carry therapeutic payloads — proteins that trigger cancer cell death or recruit immune cells to the tumor site — researchers aim to create a treatment that concentrates its effects precisely where needed.

The Dog Aging Project Connection

The Dog Aging Project, which received a $7 million NIH grant in 2025, is also generating data relevant to canine cancer research. Its longitudinal study of over 45,000 companion dogs is identifying how aging, genetics, and environment interact to influence cancer risk.

The project’s TRIAD clinical trial — testing whether low-dose rapamycin can slow aging in dogs — has implications for cancer prevention. Rapamycin, which inhibits the mTOR pathway involved in cell growth and proliferation, has shown anti-cancer properties in laboratory studies. If the trial demonstrates that rapamycin delays age-related disease onset in dogs, cancer could be among the conditions affected.

What This Means for Dog Owners Now

While these immunotherapy advances are still in research stages, dog owners can take action today to improve cancer outcomes for their pets.

Know the warning signs — Lumps that grow rapidly, wounds that do not heal, unexplained weight loss, persistent lameness, abnormal swelling, and bleeding from any body opening all warrant immediate veterinary evaluation. Early detection dramatically improves prognosis. Familiarize yourself with our common dog health problems guide for a comprehensive symptom checklist.

Perform monthly body checks — Run your hands over your dog’s entire body at least once a month, feeling for new lumps, bumps, or areas of tenderness. This is especially important for breeds predisposed to mast cell tumors.

Maintain healthy weight — Obesity increases cancer risk in dogs just as it does in humans. Keep your dog at a healthy body condition through appropriate feeding and regular exercise. Our dog weight management guide covers practical strategies by breed size.

Consider genetic health screening — If you own a breed with elevated cancer risk, discuss screening options with your veterinarian. Some genetic tests can identify predisposition to specific cancer types, allowing for earlier surveillance.

Ask about clinical trials — If your dog is diagnosed with cancer, ask your veterinarian or a veterinary oncologist about available clinical trials. Participating in research gives your dog access to cutting-edge treatments while advancing the science that will help future dogs. The Morris Animal Foundation and veterinary teaching hospitals maintain registries of active trials.

The Bigger Picture

Canine cancer immunotherapy research benefits more than dogs. Because dogs develop cancers that closely parallel human cancers — genetically, behaviorally, and in their response to treatment — breakthroughs in veterinary oncology often translate directly to human medicine. Dogs and humans share the same environments, eat similar diets, and age in comparable ways, making companion dogs one of the most valuable models for understanding and treating cancer across species.

The 2026 animal health outlook from Morris Animal Foundation identifies cancer as the single largest health threat facing companion animals and the area where investment in new approaches is most urgently needed. The immunotherapy research funded this year represents a meaningful step toward a future where cancer in dogs is treatable, manageable, and ultimately preventable.

Sources

1. New Canine Health Studies Funded for 2026 — Morris Animal Foundation — accessed March 26, 2026
2. Engineering a Monoclonal Antibody Therapy for Canine Mast Cell Tumors — Morris Animal Foundation — accessed March 26, 2026
3. Dog Aging Project receives $7M NIH grant — Texas A&M — accessed March 26, 2026
4. Looking Ahead to 2026: Animal Health Outlook — Morris Animal Foundation — accessed March 26, 2026